Neurotechnology

The brain-computer interface field has captured serious investor imagination. Companies are developing interfaces using implanted electrodes, ultrasound, and engineered molecules, and hundreds of millions of dollars have flowed in over the past three years. The investors funding this race are not primarily motivated by helping people with ALS or spinal cord injury — they are betting on a mass consumer market: thought-to-text, memory upload, AI symbiosis for healthy adults.  A

How hybrid biological-artificial intelligence systems could transform medical AI by learning the way humans do Part I: The Vision (TL;DR)...

DRAFT WHITE PAPER: Prepared for the Implantable Brain-Computer Interface Collaborative Community (iBCI-CC) Executive Summary As invasive...

As invasive brain-computer interface (iBCI) companies race toward FDA approval, they face a critical strategic decision that will...

A comprehensive blueprint for creating sustainable, evidence-based pain rehabilitation programs that serve patients, preserve surgical...

Part I: The Vision - A New Paradigm for Neurological Recovery The Problem We Must Solve Millions of people live with neurological...

What if the next leap in computing doesn’t come from faster GPUs or more efficient transformer models, but from a living system that...

A roadmap for navigating the bandwidth bottleneck between biological and artificial intelligence Neural tissue and silicon firmware can communicate directly with each other both in vitro and in vivo. © 2025, Mijail D. Serruya The Fundamental Problem Current brain-computer interfaces are impressive—and we can ask: are they 'just' a more direct equivalent to screen-and-keyboard, or are something fundamentally different? Are we trying to squeeze the entire ba

"I have a queer sensation as if I am not here... As though I were half here and half not here." When Wilder Penfield's electrode touched...

TL;DR : With nearly $1 billion invested in implantable brain-computer interfaces, investors expect a 10x return on a $10 billion market. Yet the path to this scale requires fundamental shifts beyond technical innovation—from regulatory frameworks to reimbursement models, from device-centric thinking to platform ecosystems, and from passive medical devices to living pharmaceutical systems that partner with human agency. The Cochlear Implant Benchmark: A 70-Year Reality Check W

I do not think it is possible to strip the discovery of new knowledge from the cultural and political context of which emerges, and I do...